September 23, 2024
MILAN — Psilocybin leads to a better overall outcome in the treatment of moderate to severe major depressive disorder (MDD) than the selective serotonin reuptake inhibitor […]
September 20, 2024
The US Food and Drug Administration (FDA) is due to issue a decision by September 26 on the approval of KarXT, a potential first-in-class antipsychotic. If […]
September 17, 2024
TOPLINE: Antipsychotic use for schizophrenia or other psychotic disorders is associated with increased risk for severe COVID-19 or other respiratory infection and related hospitalization, a new […]
September 13, 2024
US suicide rates have reached alarming levels, with data from Centers for Disease Control and Prevention (CDC) showing a 37% increase from 2000 to 2022. Nearly […]
September 13, 2024
TOPLINE: In 2022, nearly 22% of people who died of drug overdose had a non–substance-related mental health disorder (MHD), new data from the US Centers for […]
September 12, 2024
Teenagers and young adults taking high doses of prescription amphetamines may face a greater than fivefold increased risk of developing psychosis or mania, a new analysis […]
September 6, 2024
Researchers have discovered that a brain network involved in reward processing and attention to stimuli is markedly bigger in people with depression, remains stable over time, […]
September 5, 2024
TOPLINE: A self-guided mobile application for cognitive behavioral therapy (CBT) is associated with significant reductions in anxiety in young adults with anxiety disorders after 3 weeks, […]
September 4, 2024
(Reuters) – The U.S. Drug Enforcement Administration (DEA) has increased the production limit for Takeda Pharmaceutical’s ADHD drug Vyvanse and its generic versions by about 24% […]